Updated EAS consensus statement on homozygous familial hypercholesterolemia

The European Atherosclerosis Society (EAS) published a consensus statement on homozygous familial hypercholesterolemia (HoFH) in the European Heart Journal [1], updating the previous statement from 2014.

Since the previous statement, progress has been made in the understanding of the genetic complexity of HoFH and new treatments have been developed. However, persistent questions in HoFH care remain present. Last year, a retrospective cohort study of 751 patients with HoFH from 38 countries demonstrated that underdiagnosis and undertreatment of HoFH remains a current problem in HoFH care [2]. The updated EAS statement provides clinical guidance for early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.

References

Find the 2023 EAS consensus statement at Eur Heart J.